A 3‐Decade, Single‐Center Experience of Liver Transplantation for Cholangiocarcinoma: Impact of Era, Tumor Size, Location, and Neoadjuvant Therapy

Takahiro Ito, James R. Butler, Daisuke Noguchi, Minah Ha, Antony Aziz, Vatche G. Agopian, Joseph DiNorcia, Hasan Yersiz, Douglas G. Farmer, Ronald W. Busuttil, Johnny C. Hong, Fady M. Kaldas – 4 September 2021 – Liver transplantation (LT) for cholangiocarcinoma (CCA) remains limited to a small number of centers. Although the role of neoadjuvant therapy (NAT) has been explored over time, an in‐depth analysis of NAT strategies remains limited. Furthermore, controversy exists regarding acceptable tumor size during patient selection for LT.

The Effect of Acuity Circles on Deceased Donor Transplant and Offer Rates Across Model for End‐Stage Liver Disease Scores and Exception Statuses

Andrew Wey, Samantha Noreen, Sommer Gentry, Matt Cafarella, James Trotter, Nicholas Salkowski, Dorry L. Segev, Ajay Israni, Bertram Kasiske, Ryutaro Hirose, Jon Snyder – 4 September 2021 – Acuity circles (AC), the new liver allocation system, was implemented on February 4, 2020. Difference‐in‐differences analyses estimated the effect of AC on adjusted deceased donor transplant and offer rates across Pediatric End‐Stage Liver Disease (PELD) and Model for End‐Stage Liver Disease (MELD) categories and types of exception statuses.

Comprehensive characterization of viral integrations and genomic aberrations in HBV‐infected intrahepatic cholangiocarcinomas

Jihyun An, Deokhoon Kim, Bora Oh, Yoo‐Jin Oh, Jihyun Song, Naomi Park, Ha Il Kim, Hyo Jeong Kang, Ji‐Hye Oh, Wonkyung Kim, Eunjung Lee, Chang Ohk Sung, Gi‐Won Song, Dae‐Ghon Kim, Eunsil Yu, Eric Letouzé, Jessica Zucman‐Rossi, Han Chu Lee, Ju Hyun Shim – 2 September 2021

LiverLearning®: 2021 Webinar: Biliary Atresia: Where We Are and Where Do We Go from Here?

Biliary atresia (BA) is a rapidly progressive inflammatory fibro-obliterative process affecting intra and extra hepatic bile ducts. BA is the most common indication for liver transplantation in children, however the etiopathogenesis is not completely understood. This one hour webinar will summarize genomics in BA, current diagnostic algorithms and novel prognosticators for BA, and long term outcomes of BA. Learners will gain understanding of current practices and future directions in etiopathogenesis and outcomes of BA.Kathleen M. Loomes Kathleen M.

Quantification of polyreactive immunoglobulin G facilitates the diagnosis of autoimmune hepatitis

Richard Taubert, Bastian Engel, Jana Diestelhorst, Katharina L. Hupa‐Breier, Patrick Behrendt, Niklas T. Baerlecken, Kurt‐Wolfram Sühs, Maciej K. Janik, Kalliopi Zachou, Marcial Sebode, Christoph Schramm, María‐Carlota Londoño, Sarah Habes, the UK‐AIH Consortium, Ye H. Oo, Claudine Lalanne, Simon Pape, Maren Schubert, Michael Hust, Stefan Dübel, Mario Thevis, Danny Jonigk, Julia Beimdiek, Falk F. R. Buettner, Joost P. H. Drenth, Luigi Muratori, David H. Adams, Jessica K. Dyson, Amédée Renand, Isabel Graupera, Ansgar W. Lohse, George N.

Wilson’s Disease: An Analysis of Health Care Use and Cost Burden of Commercially Insured Adults in the United States

Vinod K. Rustgi, Kapil Gupta, Christopher Tait, Abhishek Bhurwal, Savan Kabaria, Carolyn Catalano, You Li, Carlos D. Minacapelli – 1 September 2021 – The economic and health care use burdens of Wilson’s disease (WD) are unknown. In this study, we aimed to quantify this health care resource use and economic burden. We performed a retrospective case‐control analysis of individuals in the Truven Health MarketScan Commercial Claims database (2007‐2017). Using propensity scores, 424 WD cases were matched 1:1 to chronic liver disease (CLD) controls without WD.

Subscribe to